Reversion of primary hyperfibrinogenolysis in patients with hormone- refractory prostate cancer using docetaxel

Cancer Investigation

Volumn 18, Issue 3, 2000, Pages 191-196

  Sallah, Sabah ^a   Gagnon, Gregory A ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; DOCETAXEL; ESTRAMUSTINE; FIBRINOGEN; FLUTAMIDE; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE; PLASMINOGEN; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

AGED; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; FIBRINOGENOLYSIS; HUMAN; MALE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; TREATMENT FAILURE;

EID: 0034063382     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009031823     Document Type: Article

References (12)

1. Schmitt M, Harbeck N, Thomssen C, et al: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997.
2. Duffy MJ: Proteases as prognostic markers in cancer. Clin Cancer Res 2: 613-618, 1996.
3. Van Veldhuizen PJ, Sadasivan R, Cherian R, et al: Urokinase-type plasminogen activator expression in human prostate carcinomas. Am J Med Sci 312:8-11, 1996.
4. Kwaan HU, Keer HN, Radosevich JR, et al: Components of the plasminogen-plasmin system in human tumor cell lines. Semin Thromb Hemost 17:175-181, 1991.
5. Zacharski LR, Wojtukiewicz MS, Constanti V, et al: Pathways of coagulation/fibrinolysis activation in neoplasia. Semin Thromb Hemost 18:104-116, 1992.
6. Bell RW: The fibrinolytic system in neoplasia. Semin Thromb Hemost 22:459-473, 1996.
7. Stump DC, Taylor FB, Nesheim ME, et al: Pathologic fibrinolysis as a cause of clinical bleeding. Semin Thromb Hemost 16:260-263, 1990.
8. Rosen JP: Bleeding problems in the cancer patient. Hematol/Oncol Clin North Am 6:1315-1328, 1992.
9. Cortez JE, Pazdier R: Docetaxel. J Clin Oncol 13:243-255, 1995.
10. Cooper DL, Sandler AB, Wilson LD, et al: Disseminated intravascular coagulation and excessive fibrinolysis in a patient with metastatic prostate cancer. Response to epsilon-aminocarporic acid. Cancer 70:656-658, 1992.
11. Lowe CF, Somers JW: The use of ketoconazole in the emergency management of disseminated intravascular coagulation due to metastatic prostate cancer. J Urol 137:1000-1002, 1987.
12. Litt MR, Bell WR, Lepor HR: Disseminated intravascular coagulation in prostatic carcinoma reversed by ketoconazole. JAMA 258:1361-1362, 1987.